Jul 8, 2024, 16:34
Aref Al-Kali: AML is hanging with use of FLT3i and Allo BMT
Aref Al-Kali, Hematologist/Oncologist at Mayo Clinic, shared on X:
“Outcome of t6;9 AML changing with use of FLT3i and Allo BMT. Plan for larger multisite study lead by Clifford Csizmar.
FLT3 inhibitors potentially improve response rates in acute myeloid leukemia harboring t(6;9)(DEK::NUP214).”
Source: Aref Al-Kali/X
Authors:
Abhishek A Mangaonkar
Alexandra P Wolanskyj-Spinner
AML
Animesh Pardanani
Antoine N Saliba
Aref Al-Kali
Ayalew Tefferi
BMT
C Christopher Hook
cancer
Clifford Csizmar
Clifford M Csizmar
FLT3i
Hassan Alkhateeb
James M Foran
Jeanne M Palmer
Kebede H Begna
Mark R Litzow
Mayo Clinic
Mehrdad Hefazi Torghabeh
Mithun V Shah
Mrinal M Patnaik
Naseema Gangat
OncoDaily
Oncology
Patricia T Greipp
Scott H Kaufmann
William J Hogan
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 14:55
Nov 13, 2024, 14:47
Nov 13, 2024, 14:43
Nov 13, 2024, 14:37
Nov 13, 2024, 14:05
Nov 13, 2024, 12:13
Nov 13, 2024, 11:52
Nov 13, 2024, 11:48
Nov 13, 2024, 11:44